Aclaris Therapeutics Inc ACRS
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-10-07 |
| Shares Out. | 139,660,000 |
| Website | aclaristx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 73 |
| Revenue | $2.0M |
| Gross Profit | $1.6M |
| Net Income | -$19.8M |
| Free Cash Flow | -$52.0M |
| Total Assets | $198.7M |
| Total Liabilities | $55.1M |
| Equity | $143.6M |
About Aclaris Therapeutics Inc
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Aclaris Therapeutics Inc is a publicly traded company under the ticker symbol ACRS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)